You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Boehringer Ingelheim
Moodys
Express Scripts
Mallinckrodt

Last Updated: March 2, 2021

DrugPatentWatch Database Preview

Mebendazole - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic sources for mebendazole and what is the scope of patent protection?

Mebendazole is the generic ingredient in two branded drugs marketed by Impax Labs Inc and Janssen Pharms, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.

There are nine drug master file entries for mebendazole. Three suppliers are listed for this compound.

Summary for mebendazole
US Patents:0
Tradenames:2
Applicants:2
NDAs:3
Drug Master File Entries: 9
Suppliers / Packagers: 3
Bulk Api Vendors: 124
Clinical Trials: 27
Patent Applications: 4,855
Formulation / Manufacturing:see details
What excipients (inactive ingredients) are in mebendazole?mebendazole excipients list
DailyMed Link:mebendazole at DailyMed
Recent Clinical Trials for mebendazole

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Institute of Liver and Biliary Sciences, IndiaN/A
Centre de Recherche Médicale de LambarénéPhase 4
Swiss Tropical & Public Health InstitutePhase 2

See all mebendazole clinical trials

Pharmacology for mebendazole
Drug ClassAnthelmintic
Medical Subject Heading (MeSH) Categories for mebendazole

US Patents and Regulatory Information for mebendazole

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Impax Labs Inc EMVERM mebendazole TABLET, CHEWABLE;ORAL 073580-001 Jan 4, 1995 RX No Yes   Start Trial   Start Trial   Start Trial
Janssen Pharms VERMOX mebendazole TABLET, CHEWABLE;ORAL 017481-001 Approved Prior to Jan 1, 1982 DISCN Yes No   Start Trial   Start Trial   Start Trial
Janssen Pharms VERMOX mebendazole TABLET, CHEWABLE;ORAL 208398-001 Oct 19, 2016 DISCN Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
McKesson
Johnson and Johnson
Boehringer Ingelheim
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.